State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
- Author:
Yongin CHO
1
;
Yong-ho LEE
Author Information
- Publication Type:Review Article
- From:Endocrinology and Metabolism 2022;37(1):38-52
- CountryRepublic of Korea
- Language:English
- Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.
